Andromeda Acquires DiaPep277 Rights From Teva
February 24, 2014 04:13 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for...
Andromeda Announces the Acceptance of Two Manuscripts for Publication Describing Its Phase 3 DIA-AID 1 Study
January 12, 2014 09:12 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, Jan. 12, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that two peer-reviewed articles were accepted for publication in Diabetes Care. The publications, which discuss...
Andromeda Announces First Patient Dosed in Extension Study to Its Phase 3 Clinical Trial DIA-AID 2 in Patients With Type 1 Diabetes
December 18, 2013 08:32 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the first patient was dosed with DiaPep277® for the treatment of type 1 diabetes in its Extension...
Andromeda Announces the Results of an Extension to Its Phase III Study
June 05, 2013 07:19 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, June 5, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces the results from an Extension Study to its Phase III Clinical trial in type 1 diabetes patients treated with...
Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Confirmatory Trial for Its Lead Drug, "DiaPep277" for Type 1 Diabetes
September 12, 2012 03:34 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. (www.andromedabio.com) announced today that it has completed patient recruitment in its' DIA-AID 2, a confirmatory Phase III...
Andromeda Announces FDA Orphan Drug Designation for DiaPep277 for the Treatment of Type 1 Diabetes With Residual Beta Cell Function
May 28, 2012 06:45 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, May 28, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the US Food and Drug Administration (FDA) granted Orphan Drug designation for DiaPep277® for the...
Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study
May 09, 2012 12:21 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, May 9, 2012 (GLOBE NEWSWIRE) -- Clal Biotechnology Industries Ltd. today announces that further analyses of initial data support the achieved primary endpoint of Andromeda Biotech's...
Andromeda Announces Phase III Clinical Study With DiaPep277(R), a Novel Immunotherapeutic Agent for Type 1 Diabetes, Met Primary Endpoint
November 22, 2011 10:38 ET
|
Andromeda Biotech Ltd.
DiaPep277® Demonstrated a Significant Preservation of C-peptide Levels, a Marker for Assessing Insulin Secretion by Pancreatic Cells
Higher Proportion of Patients Maintained Adequate Diabetic...
Teva Exercises Option to Invest in Andromeda Biotech
June 17, 2010 07:41 ET
|
Andromeda Biotech Ltd.
YAVNE, Israel, June 17, 2010 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd....